Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Liabilities-to-Assets Related Terms
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Liabilities-to-Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Liabilities-to-Assets Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
IST:ONCSM vs ABT, SYK, MDT: Liabilities-to-Assets Comparison
For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Liabilities-to-Assets vs Medical Devices & Instruments Industry
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a Liabilities-to-Assets of 0.44 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Liabilities-to-Assets too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Liabilities-to-Assets is 0.44. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Liabilities-to-Assets compare to ABT and SYK?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Liabilities-to-Assets of 0.44 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Liabilities-to-Assets is 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺256.15, compared to a current price of ₺252.75 — trading 1.3% below its estimated fair value. The current Liabilities-to-Assets is 0.44. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current Liabilities-to-Assets is 0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued.
The current stock price of ₺252.75 is trading 1.3% below its estimated GF Value™ of ₺256.15.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:ONCSM:
Liabilities-to-Assets: 0.44
GF Value™: ₺256.15 vs. price of ₺252.75 (1.3% below fair value)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
